{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:15:53Z","timestamp":1788477353815,"version":"build-2803163510"},"reference-count":52,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014116","name":"Ontario Veterinary College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014116","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ontario Graduate Scholarship, Ontario Ministry of Agriculture and Rural Affairs Highly Qualified"},{"name":"Skies Cancer Fund and the Pet Trust Foundation"},{"name":"Science Without Borders Program"},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"crossref","award":["436264"],"award-info":[{"award-number":["436264"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000038","name":"NSERC","doi-asserted-by":"crossref","award":["499834"],"award-info":[{"award-number":["499834"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,2,12]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Novel therapies are needed to improve outcomes for women diagnosed with ovarian cancer. Oncolytic viruses are multifunctional immunotherapeutic biologics that preferentially infect cancer cells and stimulate inflammation with the potential to generate antitumor immunity. Herein we describe <jats:italic>Parapoxvirus ovis<\/jats:italic> (Orf virus (OrfV)), an oncolytic poxvirus, as a viral immunotherapy for ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The immunotherapeutic potential of OrfV was tested in the ID8 orthotopic mouse model of end-stage epithelial ovarian carcinoma. Immune cell profiling, impact on secondary lesion development and survival were evaluated in OrfV-treated mice as well as in Batf3 knockout, mice depleted of specific immune cell subsets and in mice where the primary tumor was removed. Finally, we interrogated gene expression datasets from primary human ovarian tumors from the International Cancer Genome Consortium database to determine whether the interplay we observed between natural killer (NK) cells, classical type 1 dendritic cells (cDC1s) and T cells exists and influences outcomes in human ovarian cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>OrfV was an effective monotherapy in a murine model of advanced-stage epithelial ovarian cancer. OrfV intervention relied on NK cells, which when depleted abrogated antitumor CD8<jats:sup>+<\/jats:sup> T-cell responses. OrfV therapy was shown to require cDC1s in experiments with BATF3 knockout mice, which do not have mature cDC1s. Furthermore, cDC1s governed antitumor NK and T-cell responses to mediate antitumor efficacy following OrfV. Primary tumor removal, a common treatment option in human patients, was effectively combined with OrfV for optimal therapeutic outcome. Analysis of human RNA sequencing datasets revealed that cDC1s correlate with NK cells in human ovarian cancer and that intratumoral NK cells correlate positively with survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The data herein support the translational potential of OrfV as an NK stimulating immunotherapeutic for the treatment of advanced-stage ovarian cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-004335","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T12:11:00Z","timestamp":1647432660000},"page":"e004335","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct00408590","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01274624","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03663712","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00964756","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02759588","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jacob P","family":"van Vloten","sequence":"first","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Matuszewska","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A A","family":"Minow","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A","family":"Minott","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Santry","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Pereira","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley A","family":"Stegelmeier","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"McAusland","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M","family":"Klafuric","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Karimi","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Colasanti","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D Grant","family":"McFadden","sequence":"additional","affiliation":[{"name":"Biodesign Institute, Arizona State University, Tempe, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Petrik","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byram W","family":"Bridle","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-2406","authenticated-orcid":false,"given":"Sarah K","family":"Wootton","sequence":"additional","affiliation":[{"name":"Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"2025100308324683000_10.3.e004335.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.02.001"},{"key":"2025100308324683000_10.3.e004335.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2008.058248"},{"key":"2025100308324683000_10.3.e004335.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2007.01499.x"},{"key":"2025100308324683000_10.3.e004335.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00322","article-title":"Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer","volume":"4","author":"Ohman","year":"2014","journal-title":"Front Oncol"},{"key":"2025100308324683000_10.3.e004335.5","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2013.24.1.83"},{"key":"2025100308324683000_10.3.e004335.6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0960-z"},{"key":"2025100308324683000_10.3.e004335.7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3432"},{"key":"2025100308324683000_10.3.e004335.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.011"},{"key":"2025100308324683000_10.3.e004335.9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: a systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100308324683000_10.3.e004335.10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"2025100308324683000_10.3.e004335.11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00106"},{"key":"2025100308324683000_10.3.e004335.12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1146\/annurev-cancerbio-030518-055653","article-title":"Natural killer cells in cancer immunotherapy","volume":"3","author":"Lanier","year":"2019","journal-title":"An Rev Cancer Biol"},{"key":"2025100308324683000_10.3.e004335.13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"2025100308324683000_10.3.e004335.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI99317"},{"key":"2025100308324683000_10.3.e004335.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0062"},{"key":"2025100308324683000_10.3.e004335.16","doi-asserted-by":"publisher","DOI":"10.1177\/1753425915575078"},{"key":"2025100308324683000_10.3.e004335.17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/imt.14.122","article-title":"Bidirectional interactions of NK cells and dendritic cells in immunotherapy: current and future perspective","volume":"7","author":"Mahmood","year":"2015","journal-title":"Immunotherapy"},{"key":"2025100308324683000_10.3.e004335.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003"},{"key":"2025100308324683000_10.3.e004335.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0085-8"},{"key":"2025100308324683000_10.3.e004335.20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cdc1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"2025100308324683000_10.3.e004335.21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14754"},{"key":"2025100308324683000_10.3.e004335.22","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.301"},{"key":"2025100308324683000_10.3.e004335.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1993"},{"key":"2025100308324683000_10.3.e004335.24","doi-asserted-by":"crossref","first-page":"434-447","DOI":"10.1016\/j.omtm.2021.08.004","article-title":"Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy","volume":"23","author":"van Vloten","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100308324683000_10.3.e004335.25","doi-asserted-by":"publisher","DOI":"10.1007\/BF01863914"},{"key":"2025100308324683000_10.3.e004335.26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2043-9113-2-5","article-title":"Monte Carlo simulation of the Spearman-Kaerber TCID50","volume":"2","author":"Wulff","year":"2012","journal-title":"J Clin Bioinforma"},{"key":"2025100308324683000_10.3.e004335.27","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1749-6632.1957.tb49710.x","article-title":"Interpretation of host response in quantitative studies on animal viruses","volume":"69","author":"Bryan","year":"1957","journal-title":"Ann N Y Acad Sci"},{"key":"2025100308324683000_10.3.e004335.28","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0864"},{"key":"2025100308324683000_10.3.e004335.29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.omtm.2019.01.012","article-title":"Quantifying antigen-specific T cell responses when using Antigen-Agnostic immunotherapies","volume":"13","author":"van Vloten","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100308324683000_10.3.e004335.30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omtm.2019.06.010","article-title":"Quantifying antibody responses induced by Antigen-Agnostic immunotherapies","volume":"14","author":"van Vloten","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025100308324683000_10.3.e004335.31","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"2025100308324683000_10.3.e004335.32","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbs046"},{"key":"2025100308324683000_10.3.e004335.33","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2014-15-1-r1"},{"key":"2025100308324683000_10.3.e004335.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.007"},{"key":"2025100308324683000_10.3.e004335.35","doi-asserted-by":"publisher","DOI":"10.1096\/fj.14-261636"},{"key":"2025100308324683000_10.3.e004335.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0220"},{"key":"2025100308324683000_10.3.e004335.37","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.ymthe.2018.03.007","article-title":"The immune system in oncolytic immunovirotherapy: gospel, schism and heresy","volume":"26","author":"Vile","year":"2018","journal-title":"Mol Ther"},{"key":"2025100308324683000_10.3.e004335.38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.3581"},{"key":"2025100308324683000_10.3.e004335.39","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2025100308324683000_10.3.e004335.40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200940153"},{"key":"2025100308324683000_10.3.e004335.41","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.12.1685"},{"key":"2025100308324683000_10.3.e004335.42","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0341"},{"key":"2025100308324683000_10.3.e004335.43","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1220467"},{"key":"2025100308324683000_10.3.e004335.44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-1536"},{"key":"2025100308324683000_10.3.e004335.45","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.60"},{"key":"2025100308324683000_10.3.e004335.46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00368"},{"key":"2025100308324683000_10.3.e004335.47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124677"},{"key":"2025100308324683000_10.3.e004335.48","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat8116","article-title":"Human natural killer cells mediate adaptive immunity to viral antigens","volume":"4","author":"Nikzad","year":"2019","journal-title":"Sci Immunol"},{"key":"2025100308324683000_10.3.e004335.49","doi-asserted-by":"crossref","DOI":"10.1186\/1746-6148-8-114","article-title":"Orf virus interferes with MHC class I surface expression by targeting vesicular transport and Golgi","volume":"8","author":"Rohde","year":"2012","journal-title":"BMC Vet Res"},{"key":"2025100308324683000_10.3.e004335.50","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2366"},{"key":"2025100308324683000_10.3.e004335.51","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"2025100308324683000_10.3.e004335.52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155189"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T15:32:59Z","timestamp":1759505579000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,16]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-004335"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004335","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}